Loading...
•
Jun 30, 2024
Esperion Q2 2024 Earnings Report
Esperion's financial performance significantly improved, marked by substantial revenue growth and strategic financial maneuvers.
Key Takeaways
Esperion reported a strong second quarter in 2024, highlighted by a 186% increase in total revenue to $73.8 million compared to the same period last year. The company also monetized its European royalties for $304.7 million and used the proceeds to pay off its Oberland revenue interest facility, enhancing financial flexibility. U.S. net product revenue grew by 39%, driven by increased retail prescription growth.
Total revenue increased by 186% year-over-year to $73.8 million.
U.S. net product revenue grew by 39% year-over-year, reaching $28.3 million.
European royalties were monetized for $304.7 million, facilitating the payoff of the Oberland revenue interest facility.
Retail prescription equivalents increased by 14% from the first quarter, with an 11% increase in the final four weeks of the second quarter.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income